deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03539302

INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT) (INSTANT)

A Prospective Randomized Multicenter Study of Flecainide Acetate Oral Inhalation Solution in Single and Repeat Dose Regimens for Acute Conversion to Sinus Rhythm in Subjects With Recent Onset of Symptomatic Paroxysmal Atrial Fibrillation

Sponsor: InCarda Therapeutics, Inc.

Conditions Paroxysmal Atrial Fibrillation (PAF)
Interventions Flecainide Acetate
Updated 18 times since 2018 Last updated: Apr 18, 2024 Started: May 29, 2018 Primary completion: Jan 17, 2022 Completion: Jan 17, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Paroxysmal Atrial Fibrillation (PAF), this trial is completed. The trial is conducted by InCarda Therapeutics, Inc. and has accumulated 18 data snapshots since 2018. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Sep 2019 · 7 months · monthly snapshot~Sep 2019 – ~Dec 2019 · 3 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Jan 2023 · 11 months · monthly snapshot~Jan 2023 – ~Dec 2023 · 11 months · monthly snapshot~Dec 2023 – ~Jun 2024 · 6 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2023 — Jun 2024 [monthly]

    Completed PHASE2

  5. Jan 2023 — Dec 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 13 earlier versions

  1. Feb 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Sep 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  3. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  4. Feb 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  5. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  6. Feb 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  7. Dec 2019 — Feb 2020 [monthly]

    Recruiting PHASE2

  8. Sep 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  9. Feb 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  10. Nov 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  11. Aug 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  12. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  13. Jun 2018 — Jul 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

May 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • InCarda Therapeutics, Inc.
Data source: InCarda Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations